A detailed history of Squarepoint Ops LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Squarepoint Ops LLC holds 73,525 shares of KYMR stock, worth $3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
73,525
Previous 108,563 32.27%
Holding current value
$3 Million
Previous $3.24 Million 7.38%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$30.16 - $52.4 $1.06 Million - $1.84 Million
-35,038 Reduced 32.27%
73,525 $3.48 Million
Q2 2024

Aug 14, 2024

BUY
$29.85 - $39.42 $695,863 - $918,959
23,312 Added 27.35%
108,563 $3.24 Million
Q1 2024

May 15, 2024

BUY
$22.9 - $43.57 $1.31 Million - $2.49 Million
57,053 Added 202.33%
85,251 $3.43 Million
Q4 2023

Feb 14, 2024

BUY
$10.97 - $26.84 $309,332 - $756,834
28,198 New
28,198 $717,000
Q4 2022

Feb 14, 2023

SELL
$19.57 - $30.92 $1.9 Million - $3 Million
-97,003 Reduced 81.6%
21,878 $546,000
Q3 2022

Nov 14, 2022

BUY
$20.91 - $34.27 $827,053 - $1.36 Million
39,553 Added 49.86%
118,881 $2.59 Million
Q2 2022

Aug 15, 2022

BUY
$14.13 - $42.55 $1.12 Million - $3.38 Million
79,328 New
79,328 $1.56 Million
Q4 2021

Feb 14, 2022

SELL
$49.91 - $65.56 $723,645 - $950,554
-14,499 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$47.8 - $66.66 $1.64 Million - $2.29 Million
-34,316 Reduced 70.3%
14,499 $852,000
Q2 2021

Aug 16, 2021

BUY
$31.08 - $51.95 $1.07 Million - $1.79 Million
34,404 Added 238.73%
48,815 $2.37 Million
Q1 2021

May 17, 2021

BUY
$35.64 - $85.46 $513,608 - $1.23 Million
14,411 New
14,411 $560,000
Q4 2020

Feb 16, 2021

SELL
$28.07 - $87.83 $253,893 - $794,422
-9,045 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$26.1 - $33.28 $236,074 - $301,017
9,045 New
9,045 $292,000

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.23B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.